Skip to main content
SpringerLink
Log in

Effects of josamycin on carbamazepine kinetics

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The steady state pharmacokinetics of oral carbamazepine in epileptic patients (n=8) was compared before and after one week of treatment with josamycin (2 g/day). There was a small but statistically significant decrease in oral clearance of total (17%) and unbound (21.5%) drug. In spite of an unchanged AUC of 10,11-epoxide carbamazepine the ratio of metabolite to parent drug AUC was significantly decreased (20.2%). The plasma protein binding of carbamazepine and its 10,11-epoxide metabolite did not vary. The results demonstrate impairment by josamycin of the apparent clearance of carbamazepine. Care should be taken in patient receiving both carbamazepine and josamycin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Albin H, Vinçon G, Pehourcq F, Dangoumau J (1982) Influence de la josamycine sur la pharmacocinétique de la carbamazépine. Therapie 37: 151–156

    Google Scholar 

  2. Bigorie B, Aimez P, Soria RJ, Samama F, Dimaria G, Guy-Grand B, Bour H (1975) L'association triacétyloléandomycine-tartrate d'ergotamine est-elle dangereuse? Nouv Presse Med 4: 2723–2725

    Google Scholar 

  3. Brazier JL, Kofman J, Faucon G, Perin-Fayolle M, Lepape A, Lanque R (1980) Retard d'élimination de la théophylline dû à la troléandomycine. Absence d'effet de la josamycine. Therapie 35: 545–549

    Google Scholar 

  4. Dravet C, Mesdjian E, Cenraud B, Roger J (1977) Interaction carbamazépine-troléandomycine: une nouvelle interaction médicamenteuse? Nouv Presse Med 6: 567–569

    Google Scholar 

  5. Eichelbaum M, Bertilsson L (1975) Determination of carbamazepine and its epoxide metabolite in plasma by high speed liquid chromatography. J Chromatrogr 103: 135–140

    Google Scholar 

  6. Eichelbaum M, Tomson T, Tybring G, Bertilsson L (1985) Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet 10: 80–90

    Google Scholar 

  7. Faigle JW, Feldman KF (1982) Carbamazepine biotransformation. In: Woodburry EM, Penry JK, Pipenger CE (eds) Antiepileptic drugs (2nd edn). Raven Press, New York

    Google Scholar 

  8. Hayton AC (1969) Precipitation of acute ergotism by triacetyloleandomycin. NZ Med J 69: 42–43

    Google Scholar 

  9. Hooper WD, Dubetz DK, Bochner F, Cotter LM, South GA, Eadie MJ, Tyrer JM (1975) Plasma protein binding of carbamazepine. Clin Pharmacol Ther 17: 433–440

    Google Scholar 

  10. Larrey D, Funck-Brentano C, Breil P, Vitaux J, Theodore C, Babany G, Pessayre D (1983) Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 32: 1063–1068

    Google Scholar 

  11. Levy RM, Pitlick WH, Troupin AS, Green JR, Neal JM (1975) Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther 17: 657–668

    Google Scholar 

  12. Mesdjian E, Dravet C, Cenraud B, Roger J (1980) Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia 21: 489–496

    Google Scholar 

  13. Pynnönen S, Sillanpää M, Frey H, Iisola E (1977) Carbamazepine and its 10,11-epoxide in children and adults with epilepsy. Eur J Clin Pharmacol 11: 129–133

    Google Scholar 

  14. Riva R, Contin M, Albani F, Perucca E, Ambrosetto G, Gobbi G, Cortelli P, Procaccianti G, Baruzzi A (1984) Free and total plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients: Diurnal fluctuations and relationship with side-effects. Ther Drug Monit 6: 408–413

    Google Scholar 

  15. Rowland M, Tozer TN (1980) Clinical pharmacokinetics: Concepts and applications. Lea & Febiger, Philadelphia

    Google Scholar 

  16. Webster LK, Mihaly GW, Jones DB, Smallwood RA, Phillips JA, Vajda FJ (1984) Effects of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol 27: 341–343

    Google Scholar 

  17. Weinberger M, Hudgel D, Spector S, Chidsey C (1977) Inhibition of theophylline clearance by troleandomycin. J Allergy Clin Immunol 59: 228–231

    Google Scholar 

  18. Westenberg HGM, Van der Kleijn E, Oei TT, de Zeeuw R (1978) Kinetics of carbamazepine and carbamazepine-epoxide determined by use of plasma and saliva. Clin Pharmacol Ther 23: 320–328

    Google Scholar 

  19. Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390

    Google Scholar 

  20. Wong YY, Ludden TM, Bell RD (1983) Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther 33: 460–464

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Hôpital Pellegrin, Bordeaux, France

    G. Vinçon, H. Albin, F. Demotes-Mainard & C. Bistue

  2. Department of Neurology, Hôpital Pellegrin, Bordeaux, France

    M. Guyot & P. Loiseau

Authors
  1. G. Vinçon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Albin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Demotes-Mainard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Guyot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Bistue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Loiseau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vinçon, G., Albin, H., Demotes-Mainard, F. et al. Effects of josamycin on carbamazepine kinetics. Eur J Clin Pharmacol 32, 321–323 (1987). https://doi.org/10.1007/BF00607583

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00607583

Key words

Search

Navigation